$ABVX News

Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96

Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target

Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting

ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About

ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers

ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts

BTIG Reiterates Buy on Abivax, Maintains $175 Price Target

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151

Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118

Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax H1 EPS $(2.43) Misses $(1.08) Estimate, Sales $2.959M Beat $1.860M Estimate

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

ABIVAX (NASDAQ:ABVX) Flashes Strong Technical Rating and Breakout Setup

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod